Get Legal Help Now
Ozempic and Wegovy History
In 2016, Ozempic manufacturer Novo Nordisk announced the submission of a new drug application for a semaglutide-based medication to treat Type 2 diabetes. The Federal Drug Administration approved the drug in 2017, and U.S. sales began in 2018.
Shortly after its introduction to the market, healthcare professionals began to notice an unintended side effect of the semaglutide drug: appetite suppression, frequently leading to weight loss among patients.
By March 2021, Novo Nordisk completed trials and announced results indicating that adults with obesity could be treated with a similar, higher-dose semaglutide drug, Wegovy, for chronic weight management. The FDA approved the medication in June of the same year, and by December 2022, its use was approved in adolescents 12 and older with BMIs in the 95th percentile. Since then, the popularity of both drugs has skyrocketed, causing shortages on a national scale due to its use as a weight-loss medication.
Novo Nordisk disclosed Important Safety Information and provided a link to the Medication Guide and Prescribing Information in their communication with the U.S. Food and Drug Administration. However, severe gastrointestinal events, including gastroparesis and gastroenteritis, were not identified as risks in these communications.
Our experienced product liability lawyers are investigating Ozempic and Wegovy cases. If you took one of these drugs, reach out today to discuss your options.
Contact Us
Ozempic and Wegovy Negative Symptoms
While Ozempic and Wegovy have been shown to result in weight loss, they may also cause unintended and undisclosed side effects, including cyclical vomiting, stomach paralysis, gastroparesis, pancreatic cancer, Deep vein thrombosis (DVT) and intestinal blockages.
Ozempic patients have described suffering from severe gastrointestinal events, including severe vomiting, stomach pain, gastrointestinal burning, hospitalization for stomach issues, lost teeth due to excessive vomiting, additional medications to alleviate her excessive vomiting, and throwing up whole food hours after eating.
Published studies show that patients who use semaglutide drugs, such as Ozempic and Wegovy, are at an increased risk of intestinal obstructions.
Some of the effects of intestinal obstruction include:
- Indigestion
- Nausea
- Vomiting
- Malnutrition
- Bloated stomach
- Feeling full very quickly
- Upper abdominal pain
- Loss of appetite
- Constipation
The firm is presently reviewing Ozempic and Wegovy cases. If you or someone you know have experienced extreme stomach and gastrointestinal pain following the use of these drugs, please contact the reputable team of personal injury lawyers at SPBMCC to request a free consultation. We proudly serve clients nationwide.
Contact Sullivan Papain Today
We have years of experience, extensive resources, and committed attorneys to put to use toward your case. Call (646) 722-6932 anytime to request your free case review in New York City.
$13.1m
Multi-Vehicle Collision - Verdict
For our client, who lost one leg below the knee and the other above the knee. Our client was involved in a fender-bender on a highway and was standing in front of her car when, we claimed, a tractor-trailer came to a sudden stop causing another car to swerve out from behind the jackknifed tractor-trailer…
$5.9m
Injured Passenger Not Provided Seatbelt - Verdict
In favor of our client, one of nine passengers in a rental car that was only equipped with enough seatbelts for six passengers. Our client was one of the unbelted passengers seated in the cargo area of the car when it struck a disabled tractor-trailer on the roadway on a rainy night. Our client broke…
$3.5m
Pedestrian Struck in Cross-Walk - Verdict
In favor of our client, who suffered multiple bilateral leg fractures, requiring extensive hospitalization and surgery, when she was struck down by a car as she was crossing the street at the corner with a green light. The injuries left her with a one-inch shortening of the right leg.
Attorney Advertising: Prior results do not guarantee a similar outcome.